Depomed Inc (DEPO)

19.51
0.19 0.96
NASDAQ : Health Care
Prev Close 19.70
Open 19.81
Day Low/High 19.37 / 20.09
52 Wk Low/High 12.25 / 29.50
Volume 572.25K
Avg Volume 1.12M
Exchange NASDAQ
Shares Outstanding 61.37M
Market Cap 1.21B
EPS -1.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Depomed (DEPO) Weak On High Volume

Depomed (DEPO) Weak On High Volume

Trade-Ideas LLC identified Depomed (DEPO) as a weak on high relative volume candidate

Starboard Delivers Letter To Depomed Shareholders

Starboard Delivers Letter To Depomed Shareholders

Appoints Two Exceptionally Qualified Former Pharmaceutical Executives as Advisors - Robert Savage and James Tyree - Who Would Join Starboard's "All-Star" Slate as Directors if Successful at the Special Meeting

Depomed Announces Patent Trial And Appeal Board Denial Of Inter Partes Review Of NUCYNTA Patent

Depomed Announces Patent Trial And Appeal Board Denial Of Inter Partes Review Of NUCYNTA Patent

- ANDA Litigation Decision Related to this Patent Expected by September 30, 2016 -

Depomed (DEPO): Today's Weak On High Volume Stock

Depomed (DEPO): Today's Weak On High Volume Stock

Trade-Ideas LLC identified Depomed (DEPO) as a weak on high relative volume candidate

Depomed Proposes To Call Special Meeting Of Shareholders On October 28, 2016 Following Outcome Of NUCYNTA Patent Litigation

Depomed Proposes To Call Special Meeting Of Shareholders On October 28, 2016 Following Outcome Of NUCYNTA Patent Litigation

Sets Record Date to Determine Shareholders Entitled to Request Special Meeting Called by Starboard

Insider Trading Alert - DEPO, ARIA And ROG Traded By Insiders

Insider Trading Alert - DEPO, ARIA And ROG Traded By Insiders

Stocks with insider trader activity include DEPO, ARIA and ROG

Starboard Delivers Letter To Depomed Shareholders

Starboard Delivers Letter To Depomed Shareholders

Recommences the Process to Call a Special Meeting of Shareholders for Removing and Replacing the Current Depomed Board with a Modified Slate of Six Highly Qualified Nominees

Sohn Picks Revisited: Mixed Results From David Einhorn & Jeffrey Smith

Results on conference picks are split as hedge fund industry contends with criticism.

Depomed Announces District Court Order Extending Stay In NUCYNTA ANDA Litigation

Depomed Announces District Court Order Extending Stay In NUCYNTA ANDA Litigation

- Decision Expected No Later Than September 30, 2016 -

Trade-Ideas: Depomed (DEPO) Is Today's

Trade-Ideas: Depomed (DEPO) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified Depomed (DEPO) as a "perilous reversal" (up big yesterday but down big today) candidate

'Mad Money' Lightning Round: I'm Sticking With Salesforce.com

'Mad Money' Lightning Round: I'm Sticking With Salesforce.com

Cramer says Oracle under $40 is inexpensive but DepoMed is way too hard.

Jim Cramer's 'Mad Money' Recap: What Was Hated Friday Is Loved Monday

Jim Cramer's 'Mad Money' Recap: What Was Hated Friday Is Loved Monday

This market changes on a dime, Cramer says. A market without conviction can be tricky.

Barbarian At The Gate: Depomed (DEPO)

Barbarian At The Gate: Depomed (DEPO)

Trade-Ideas LLC identified Depomed (DEPO) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

Depomed Jumps After Mizuho Says Buy Amid Rising Takeover Chances

Depomed Jumps After Mizuho Says Buy Amid Rising Takeover Chances

Shares of Depomed are on the rise after research firm Mizuho upgraded shares to Buy on its view of an increased takeout probability following Starboard Value's CEO Jeffrey Smith's comments...

Depomed (DEPO) Stock Slumps in After-Hours Trading on Q1 Earnings Miss

Depomed (DEPO) Stock Slumps in After-Hours Trading on Q1 Earnings Miss

Depomed (DEPO) stock is lower in after-hours trading on Thursday following the release of its 2016 first quarter financial results.

2016 Sohn Investment Conference Live Blog: Session 2

David Einhorn, Jim Chanos presentations close out 2106's Sohn Investment Conference.

Jeffrey Smith Says It's Time to Buy Depomed and WestRock: Sohn 2016

Jeffrey Smith Says It's Time to Buy Depomed and WestRock: Sohn 2016

Activist Jeffrey Smith took the Sohn stage Wednesday highlighting stocks Starboard finds undervalued.

Commit To Purchase Depomed At $13, Earn 16.1% Annualized Using Options

Commit To Purchase Depomed At $13, Earn 16.1% Annualized Using Options

Investors considering a purchase of Depomed Inc shares, but cautious about paying the going market price of $16.37/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the December put at the $13 strike, which has a bid at the time of this writing of $1.30.

Sohn Preview: What Is Starboard Value's Jeffrey Smith Up to Next?

Sohn Preview: What Is Starboard Value's Jeffrey Smith Up to Next?

The appearance of Starboard Value's Jeffrey Smith at the Sohn Investment Conference is filled with intrigue.